Brokers Set Expectations for Nektar Therapeutics’ Q2 2017 Earnings (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) – Investment analysts at William Blair issued their Q2 2017 earnings per share estimates for shares of Nektar Therapeutics in a research note issued on Monday. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Nektar Therapeutics’ Q3 2017 earnings at ($0.35) EPS, Q4 2017 earnings at ($0.33) EPS, FY2017 earnings at ($1.46) EPS, Q1 2018 earnings at ($0.35) EPS, Q2 2018 earnings at ($0.36) EPS, Q3 2018 earnings at ($0.36) EPS, Q4 2018 earnings at ($0.36) EPS, FY2018 earnings at ($1.43) EPS and FY2019 earnings at ($1.43) EPS.

Other analysts also recently issued research reports about the stock. Jefferies Group LLC set a $25.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Saturday, April 22nd. Roth Capital set a $23.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Saturday, March 4th. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Aegis lifted their target price on shares of Nektar Therapeutics from $24.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, April 6th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $29.00 target price on shares of Nektar Therapeutics in a report on Tuesday, April 11th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and an average target price of $25.25.

COPYRIGHT VIOLATION NOTICE: This story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/18/brokers-set-expectations-for-nektar-therapeutics-q2-2017-earnings-nktr-updated-updated.html.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at 18.82 on Wednesday. The stock’s market cap is $2.92 billion. The firm’s 50-day moving average price is $19.14 and its 200-day moving average price is $16.37. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.02. The company had revenue of $24.73 million for the quarter, compared to analysts’ expectations of $29.43 million. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The firm’s quarterly revenue was down 58.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) EPS.

Institutional investors have recently bought and sold shares of the company. Elkfork Partners LLC acquired a new position in Nektar Therapeutics during the fourth quarter valued at approximately $105,000. Flinton Capital Management LLC increased its position in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the period. Meadow Creek Investment Management LLC increased its position in Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares during the period. Glen Harbor Capital Management LLC increased its position in Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares during the period. Finally, Bank of Montreal Can increased its position in Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 1,464 shares during the period. Institutional investors and hedge funds own 93.64% of the company’s stock.

In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $19.55, for a total value of $33,254.55. Following the completion of the transaction, the senior vice president now owns 32,803 shares in the company, valued at $641,298.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Maninder Hora sold 180,000 shares of the business’s stock in a transaction on Wednesday, April 5th. The stock was sold at an average price of $21.70, for a total transaction of $3,906,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 228,414 shares of company stock valued at $4,887,994. Insiders own 5.44% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply